Mucopolysaccharidosis II Clinical Trials

7 recruitingLast updated: May 21, 2026

There are 7 actively recruiting mucopolysaccharidosis ii clinical trials across 16 countries. Studies span Phase 2, Phase 3, Phase 1. Top locations include Lille, France, Çankaya, Turkey (Türkiye), Antwerp, Antwerpen, Belgium. Updated daily from ClinicalTrials.gov.


Mucopolysaccharidosis II Trials at a Glance

7 actively recruiting trials for mucopolysaccharidosis ii are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 2 with 4 trials, with the heaviest enrollment activity in Lille, Çankaya, and Antwerp. Lead sponsors running mucopolysaccharidosis ii studies include Institut National de la Santé Et de la Recherche Médicale, France, JCR Pharmaceuticals Co., Ltd., and Denali Therapeutics Inc..

Browse mucopolysaccharidosis ii trials by phase

About Mucopolysaccharidosis II Clinical Trials

Looking for clinical trials for Mucopolysaccharidosis II? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Mucopolysaccharidosis II trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Mucopolysaccharidosis II clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 2Phase 3

Phase I/II/III Gene Transfer Clinical Trial of scAAV9.U1a.hSGSH

Mucopolysaccharidosis IIIMPS IIIASanfilippo Syndrome+1 more
Ultragenyx Pharmaceutical Inc36 enrolled5 locationsNCT02716246
Recruiting

Registry of Patients Diagnosed With Lysosomal Storage Diseases

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis VI+5 more
University of California, San Francisco250 enrolled1 locationNCT05619900
Recruiting
Phase 2Phase 3

Study of Cannabidiol in Sanfilippo Syndrome

Mucopolysaccharidosis IIISanfilippo Syndrome
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center35 enrolled1 locationNCT06333041
Recruiting

MPS (RaDiCo Cohort) (RaDiCo-MPS)

Mucopolysaccharidosis IMucopolysaccharidosis IIMucopolysaccharidosis III+5 more
Institut National de la Santé Et de la Recherche Médicale, France1,000 enrolled23 locationsNCT06036693
Recruiting
Phase 1

UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells

Batten DiseaseAdrenoleukodystrophyPelizaeus-Merzbacher Disease+9 more
Joanne Kurtzberg, MD40 enrolled1 locationNCT02254863
Recruiting
Phase 1Phase 2

An Open-label Phase I/II Study of JR-446 in Mucopolysaccharidosis Type IIIB

Mucopolysaccharidosis III-B
JCR Pharmaceuticals Co., Ltd.10 enrolled3 locationsNCT06488924
Recruiting
Phase 2Phase 3

A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)

Mucopolysaccharidosis II
Denali Therapeutics Inc.63 enrolled32 locationsNCT05371613